Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following: Gleason sum at least 7 Prostate-specific antigen (PSA) at least 15 ng/mL Clinical stage T2b or T2c (stage II) Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45% At least 3 positive core biopsies Planned radical prostatectomy No metastatic disease secondary to prostate cancer PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL No history of bleeding disorders Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 1.5 times upper limit of normal No viral hepatitis Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Other: No history of hypersensitivity and/or adverse reactions to salicylates No allergy to sulfa-containing medications No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer No medical or psychiatric problem that would preclude study participation No active infection HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunologic therapy for prostate cancer Chemotherapy: At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: No prior androgen ablation for prostate cancer At least 4 weeks since prior hormonal therapy and recovered At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids No concurrent glucocorticoids Radiotherapy: At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered Surgery: See Disease Characteristics At least 4 weeks since prior major surgery and recovered Other: No prior investigational therapy for prostate cancer No prior or concurrent chronic anticoagulants No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib) At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA) At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs) At least 24 hours since prior use and no concurrent use of any of the following: Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole No aspirin (100 mg/day) within 1 week prior to surgery No concurrent addition of vitamins or herbal supplements